MICHAEL PERRAUT, M.D.

Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use

Critical care, first 30-74 minutes

Transitional care management services for problem of at least moderate complexity

Emergency department visit with high level of medical decision making

Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment

New patient office or other outpatient visit, 45-59 minutes

Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit

Emergency department visit with moderate level of medical decision making

Detection test by nucleic acid for multiple types of respiratory virus, multiple types or subtypes, 3-5 targets

Established patient office or other outpatient visit, 30-39 minutes

New patient office or other outpatient visit, 30-44 minutes

Advance care planning, first 30 minutes

Established patient office or other outpatient visit, 20-29 minutes

Simple repair of surface wound of scalp, neck, underarms, trunk, arms, or legs, 2.5 cm or less

2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r

Detection test by nucleic acid for multiple types influenza virus

Detection test by nucleic acid for multiple organisms, amplified probe(s) technique

Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus

Removal of impacted ear wax

Detection test by nucleic acid for respiratory syncytial virus, amplified probe technique

Established patient office or other outpatient visit, 10-19 minutes

Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage

2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc

Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique

Detection test by nucleic acid for organism, amplified probe technique

Injection of drug or substance under skin or into muscle

Influenza vaccine split virus, preservative free

Administration of pneumococcal vaccine

Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report

Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique

Blood test, thyroid stimulating hormone (tsh)

Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention, 5-14 minutes

Annual alcohol misuse screening, 5 to 15 minutes

Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within

Inhalation treatment for airway obstruction or sputum production

Administration and interpretation of patient-focused health risk assessment

Administration of influenza virus vaccine

Administration of vaccine

Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique

Blood test, lipids (cholesterol and triglycerides)

Blood test, comprehensive group of blood chemicals

Annual depression screening, 5 to 15 minutes

Smoking and tobacco use intensive counseling, 4-10 minutes

Detection test by immunoassay with direct visual observation for influenza virus

Influenza vaccine, quadrivalent, preservative free, 0.5 ml dosage

Thyroxine (thyroid chemical), free

Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count

Injection, ketorolac tromethamine, per 15 mg

Insertion of needle into vein for collection of blood sample

Administration of vaccine, each additional vaccine